FDA opened 72 new counterfeit cases in 2010--a new record
Caseload reinforces concerns over illegal trade and distribution of pharmaceuticals
During a presentation at a meeting organized by the Pew Prescription Project (Washington, DC., March 7-8), deputy administor Dr. Ilisa Bernstein noted that 72 cases had been opened by FDA’s Office of Criminal Investigations in FY 2010 (which ended Sept. 30). That’s up nearly 11% from the year before, which was also an up year.
FDA is always careful to not impute too much meaning to this annual count; it is a measure as much of FDA activity as it is of the pace of counterfeiting business; moreover, one “investigation” can be a single pharmacist relabeling old product as much as an international ring importing pallet-loads of product (both of which occur). Still, this count is up for three years running, and has been at a level 3-5 times what was reported a decade ago. Recent incidents also include intrusions into the so-called “normal chain of distribution” defined in various state pedigree rules; this chain is supposed to be immune to external, unregulated activity. “Counterfeiting is like water pressure,” commented Allan Coukell, a Pew Prescription Project director, during the meeting. “It will find a way in.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
